Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:59 PM
Ignite Modification Date:
2025-12-24 @ 9:59 PM
NCT ID:
NCT05125432
Eligibility Criteria:
Inclusion Criteria:
1. History of stage I-III breast cancer and free of disease by clinical examination;Currently receiving aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) treatment;
2. AI-assisted treatment has lasted for more than one month, and there are obvious symptoms of arthralgia ;
3. Voluntarily participate in the clinical trial and sign the informed consent form after informed consent (patients voluntarily accept the treatment and give informed consent);
4. Eastern Cooperative Oncology Group (ECOG) score of physical condition (0-1);
5. Patients with previous local recurrence were eligible, but not patients with distant metastasis;
6. The basic indexes were consistent, and the blood routine and ECG were normal.
Exclusion Criteria:
1. Patients with needle phobia;
2. Low platelet count (\<50000); comorbidity with a bleeding disorder; comorbidity with thyroid dysfunction; pregnancy; haemoglobin levels \<10 g/dl and haematocrit \<30; anaemia on active pharmacological treatment orreceiving blood transfusion or steroids;
3. Lymphoedematous of limbs;
4. Patients have a history of acupuncture treatment for 6 months;
5. Patients were reluctant to participate in the study;
6. A prior history of inflammation, metabolic disease, or neurotic joints, except for previous treatment with bisphosphonates, steroids, or opioid analgesics.
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT05125432
Study Brief:
Protocol Section:
NCT05125432